BLAINJECTIONINJECTABLE
Approved
Dec 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
NEMLUVIO (nemolizumab-ilto) by Galderma is interleukin-31 receptor alpha antagonists [moa]. Approved for prurigo nodularis, atopic dermatitis. First approved in 2024.
Drug data last refreshed 22h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEMLUVIO (nemolizumab-ilto) is a monoclonal antibody that blocks interleukin-31 receptor alpha, addressing the itch signal pathway in pruritic conditions. It is approved for prurigo nodularis with additional indications in atopic dermatitis, systemic sclerosis, chronic kidney disease-associated pruritus, and chronic pruritus. The drug targets a novel mechanistic pathway distinct from JAK inhibitors and immunosuppressive agents.
Growth
As a newly approved biologic in the growth phase, NEMLUVIO offers significant opportunity for field-based commercialization teams to establish market presence and capture share from JAK inhibitor-dominant competitors.
Mechanism of Action
Interleukin-31 Receptor alpha Antagonists
Indications (2)
Worked on NEMLUVIO at Galderma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.